A Phase 2 interventional study of RAP-219 in Focal Onset Seizures, sponsored by Rapport Therapeutics Inc.. Completed at 12 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-05.
Sponsored by Rapport Therapeutics Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 395 studies in Seizures with a site in United States — 75 open to participants now, 93 under way, 21 of them phase 3. Seizures · United States.
Among the 395 studies in Seizures with a site in United States, this one is the 192nd largest by enrollment of the 306 interventional ones that give a count, is one of 20 that started in 2024, is one of 64 in phase 2, and was the 349th registered.
766 studies on the registry are indexed under Seizures; 134 are open to participants now.
Browse Seizures studies →75 of the 395 studies in Seizures with a site in United States are open now. Recruiting first, the newest first:
Rapport Therapeutics Inc. · Sites in United States, Australia, Korea, Republic of
Ages 18–75
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 13–29
University of Michigan · Sites in United States
Ages 18+
The POLG Foundation · Sites in United States, Australia, Denmark and 6 more countries
Rapport Therapeutics Inc. · Sites in United States, Australia, Korea, Republic of and 1 more country
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
395 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 83 · Phase 3 94 · Phase 4 36
First in 1975; this study’s year is marked. 20 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 64 across 519 interventional studies indexed under Seizures.
Median enrollment 56 across the 306 interventional studies, 99 across the 88 observational. Of the 274 that completed or were terminated, 131 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
173 of 395 have an industry lead sponsor. The 10 most frequent:
Rapport Therapeutics Inc. is the lead sponsor of 6 studies on the registry; 4 are open to participants now.
Rapport Therapeutics Inc. has 4 studies filed under Seizures — fewer than ten, so there is no comparison to draw.
36 of the studies in Seizures with a site in United States that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06132893Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | 2026-12 |
| NCT07019922Phase 3Praxis Precision MedicinesA Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety | 2026-12 |
| NCT06660394Phase 3Longboard PharmaceuticalsA Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | 2026-12-31 |
| NCT05219617Phase 3SK Life Science, Inc.Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults | 2027-02 |
| NCT02962414Phase 3Novartis PharmaceuticalsRoll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment | 2027-02-26 |
Add all 36 to your calendar (.ics) → With an account.
Among the 395 studies in Seizures with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine if RAP-219 works and is safe in patients with Refractory Focal Epilepsy.
This is a Phase 2A, proof-of-concept, multi-center, open-label study designed to evaluate the efficacy, safety, tolerability, and PK/PD relationship of RAP-219 in adult participants with refractory focal epilepsy. The activity of RAP-219 will be assessed in approximately 30 participants treated with the RNS® system.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 0.75 mg RAP-219 daily for 5 days followed by 1.25 mg RAP-219 daily for the remainder of the 8-week treatment period.
Drug: RAP-219
RAP-219 oral tablet
Change in long episode frequency during the treatment period compared to pre-treatment baseline: Responder proportion, Percent Change Percent change
Change in long episode frequency per 28-day period during the treatment period compared to baseline
Time frame: Screening until 5 months after enrollment
Change in focal clinical seizure frequency during the treatment period compared to pre-treatment baseline: Percent Change, Responder proportion
Change in focal clinical seizure frequency per 28-day period during the treatment period compared to baseline
Time frame: Screening until 5 months after enrollment
Change in frequency of estimated electrographic seizures based on RNS® system data during the treatment period compared to pre-treatment baseline
Change in the frequency per 28-day period of estimated electrographic seizures based on RNS data during the treatment period compared to baseline
Time frame: Screening until 5 months after enrollment
Change in RNS® system long episode-free days during the treatment period compared to pre-treatment baseline: Count, Longest continuous interval, Time until pre-treatment count
Change in long episode-free days during the treatment period compared to pre-treatment baseline
Time frame: Screening until 5 months after enrollment
Change in focal clinical seizure-free days during the treatment period compared to pre-treatment baseline: Count, Longest continuous interval, Time until pre-treatment count
Change in focal clinical seizure-free days during the treatment period compared to pre-treatment baseline
Time frame: Screening until 5 months after enrollment
Change in RNS® system electrographic biomarkers other than long episodes during the treatment period compared to pre-treatment baseline
Change in RNS® system electrographic biomarkers other than long episodes during the treatment period compared to pre-treatment baseline
Time frame: Dosing until 5 months after dosing
Change in the Seizure Severity Response Questionnaire (SSRQ) during the treatment period compared to pre-treatment baseline
Measurement of seizure severity by participant rating scale of the Seizure Severity Scale. Seizure severity will be assessed by asking participants to respond to 4 questions using a 0-10 numerical rating scale and circling the number that best describes how their seizures have impacted them since their last study visit. Higher scores = higher impact.
Time frame: Screening until 5 months after enrollment
Count and proportion of responders on the clinical global impression of change (CGIC) scale during the treatment period compared to pre-treatment baseline
Change in overall clinical status as measured by Clinical Global Impression of Change scores rated by investigator and participant. Both the participant (PGIC) and the clinician (CGIC) will rate their global impression of changes in the participant's condition throughout the study. The CGI scale measures the change in the participant's clinical status from a specific point in time, i.e., the Baseline Period and is rated on a 7-point Likert scale ranging from a score of 1 for very much improved to 7 for very much worse. Higher scores = worse outcome.
Time frame: Screening until 5 months after enrollment
Plasma concentrations of RAP-219
Analysis of plasma concentrations of RAP-219
Time frame: Dosing until 5 months after dosing
Incidence of treatment-emergent adverse events (TEAEs)
Analysis of AEs during the treatment and pre-treatment baseline periods
Time frame: Dosing until 5 months after enrollment
Clinically meaningful changes, if any, from baseline in vital signs, electrocardiograms (ECGs), complete blood counts, serum chemistries, or liver function tests after treatment with RAP-219
Analysis of vital signs, ECGs, CBC, serum chemistries and liver function tests during the treatment and pre-treatment baseline periods
Time frame: Screening until 5 months after enrollment
Incidence of participants expressing suicidal ideation assessed with the Columbia-Suicide Severity Rating Scale (C-SSRS)
Analysis of C-SSRS entries during the treatment and pre-treatment baseline periods
Time frame: Screening until 5 months after enrollment
Cognitive function as measured using the Cogstate Digital Battery
Analysis of the Cogstate Digital Battery during the treatment and pre-treatment baseline periods
Time frame: Screening until 5 months after enrollment
Ran from Oct 2024 to primary completion in Sep 2025, 11 months.
Of 35 phase 2 interventional studies under Seizures, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 58. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: RAP-219
Rapport Therapeutics Inc.